Spheric Bio

Personalized medical implants grown inside body for LAAO stroke prevention

Cover Block

PUBLIC
Name Spheric Bio
Tagline Personalized medical implants grown inside body for LAAO stroke prevention
Headquarters Cambridge, MA, USA
Stage Pre-Seed
Business Model B2B
Industry Healthtech
Technology Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout
Funding Label Undisclosed

Links

PUBLIC

Executive Summary

PUBLIC

Spheric Bio is developing a platform to create personalized medical implants directly inside the human body, a technical approach that aims to solve the persistent clinical problem of one-size-fits-all devices in structural heart interventions [Deshpande Center, 2024]. The company merits attention for its academic validation in a high-stakes medtech category and its planned transition from grant-funded research to a commercial spinout. Founded by a team from MIT and Harvard, the venture is targeting left atrial appendage occlusion (LAAO) as its initial application, a procedure to prevent strokes in patients with atrial fibrillation [MIT News, Mar 2025].

The founding story is rooted in academic research, with co-founders including MIT Associate Professor Ellen Roche and HST postdoc Markus Horvath, providing a deep technical foundation in biomaterials and medical device engineering [MIT PKG Center, 2025]. The core product differentiates by using biomaterials delivered via catheter that expand and self-heal to custom-fit a patient's unique anatomy, a method the company claims can improve closure rates and reduce complications [MIT IMES, Mar 2025]. As of early 2025, the company remains in a pre-spinout, preclinical stage, having successfully tested the device in animals and won competitive academic prizes, including the MIT Sloan Healthcare Innovation Prize [MIT News, Mar 2025].

No formal equity funding rounds, investors, or a definitive business model have been publicly disclosed. The company's immediate path, according to CEO Connor Verheyen, involves spinning out from MIT, leveraging a ramp of non-dilutive grant funding into an equity seed round, and initiating studies at academic medical centers [IdeaStream, 2025]. Over the next 12-18 months, key milestones to watch include the completion of the formal spinout, the securing of a lead institutional investor, and the initiation of first-in-human clinical studies, which will test the platform's translational feasibility against established competitors.

Data Accuracy: YELLOW -- Core product claims and academic validation are documented by MIT sources; funding and commercial traction are not publicly confirmed.

Taxonomy Snapshot

Axis Classification
Stage Pre-Seed
Business Model B2B
Industry / Vertical Healthtech
Technology Type Biotech / Life Sciences
Geography North America
Growth Profile Venture Scale
Founding Team Academic Spinout

Company Overview

PUBLIC

Spheric Bio is an early-stage medical device company originating from the Massachusetts Institute of Technology and Harvard University, focused on developing a platform for personalized, in-body grown implants. The company's founding narrative is rooted in academic research, with its technology emerging from the MIT-Harvard Health Sciences and Technology (HST) program [MIT News, Mar 2025]. As of March 2025, the venture was described as planning to spin out from MIT within the year, indicating it is in a late pre-incorporation or early corporate formation phase [IdeaStream, 2025]. Its headquarters are listed in Cambridge, Massachusetts, consistent with its academic origins and the local biotech ecosystem [Deshpande Center, 2024].

The founding team combines research and early commercial leadership. Connor Verheyen is identified as the co-founder and CEO [YouTube IdeaStream, 2025]. The technical co-founders are MIT Associate Professor Ellen Roche and HST postdoctoral alumnus Markus Horvath, providing deep expertise in biomedical engineering and device development [MIT PKG Center, 2025]. The company's early validation has come primarily through academic and regional innovation competitions, serving as its initial public milestones.

Key milestones follow a path typical of university spinouts, beginning with research validation and progressing toward commercialization. The company successfully tested its implant device in animal models, a critical preclinical step [MIT IMES, Mar 2025]. It then secured non-dilutive grant funding by winning the M2D2 Challenge, a $50,000 seed funding contest run by the Massachusetts Medical Device Development Center [WB Journal]. Its most prominent recognition to date is winning the MIT Sloan Healthcare Innovation Prize (SHIP) in March 2025, which provided further validation and visibility for its personalized heart implant concept [MIT News, Mar 2025]. The stated next step is the formal spin-out from MIT, after which the company plans to initiate studies at academic medical centers [IdeaStream, 2025].

Data Accuracy: YELLOW -- Founding team and academic milestones are confirmed by multiple MIT sources; corporate status and specific spin-out timeline are based on a single presentation.

Product and Technology

MIXED

The core proposition is a platform for creating personalized medical implants that form directly inside a patient's body, moving away from standardized devices [Deshpande Center, 2024]. Its initial clinical target is left atrial appendage occlusion (LAAO), a procedure to prevent strokes in patients with atrial fibrillation where the heart's left atrial appendage is sealed off [MIT News, Mar 2025].

The proposed mechanism involves delivering biomaterials via a standard catheter; once in place, the implant expands and self-heals to conform to the unique anatomy of each patient's appendage [MIT IMES, Mar 2025]. According to CEO Connor Verheyen, this approach aims for "complete closure of the appendage for every patient, every time," with the goal of reducing device-related complications and simplifying the procedure for operators [MIT IMES, Mar 2025]. The company has reported successful animal testing of the device [MIT IMES, Mar 2025]. No technical specifications, material composition, or detailed procedural steps are publicly available.

Data Accuracy: YELLOW -- Core product claims are cited from MIT publications, but technical details on the biomaterial and self-healing mechanism lack independent verification. Animal testing is reported by a single source.

Market Research

PUBLIC, The market for left atrial appendage occlusion (LAAO) devices is a high-stakes, rapidly evolving segment within the broader structural heart intervention space, driven by a large and growing patient population with limited treatment options.

A precise, third-party TAM/SAM/SOM breakdown for Spheric Bio's specific personalized implant platform is not available in the public record. The company's initial application, LAAO for stroke prevention in atrial fibrillation (AFib) patients, targets a substantial and well-documented clinical need. The prevalence of AFib in the United States is estimated at over 6 million adults, a figure projected to rise with an aging population [CDC]. A significant portion of these patients are unsuitable for long-term anticoagulant therapy, creating a clear demand for mechanical closure devices. The global LAA closure devices market was valued at approximately $1.2 billion in 2023 and is forecast to grow at a compound annual growth rate (CAGR) of around 15% through the end of the decade, according to industry analyst reports [Grand View Research, 2024]. This serves as an analogous market sizing benchmark for the established device category Spheric Bio aims to enter.

Demand is propelled by several clinical and economic tailwinds. The primary driver is the significant stroke risk associated with AFib, coupled with the bleeding risks and compliance challenges of traditional blood thinners like warfarin and direct oral anticoagulants (DOACs). LAAO devices offer a one-time procedural solution, which is an attractive value proposition for both patients and payers concerned with long-term medication costs and monitoring. Procedural volumes for LAAO have been increasing steadily, supported by positive long-term data from registries and evolving clinical guidelines that expand the pool of eligible patients [American College of Cardiology]. Furthermore, the trend toward minimally invasive, percutaneous procedures in cardiology favors catheter-based technologies like Spheric Bio's proposed system over more invasive surgical alternatives.

The key adjacent and substitute markets are clearly defined. The direct substitute remains lifelong pharmacological anticoagulation. Adjacent markets include other structural heart interventions, such as transcatheter mitral valve repair and patent foramen ovale (PFO) closure, which share similar catheter lab infrastructure, physician operators (structural heart interventional cardiologists and electrophysiologists), and hospital procurement pathways. Success in the LAAO wedge could, in theory, pave the way for Spheric Bio's platform technology to address other anatomical sites requiring personalized, conformable implants, though no such pipeline has been publicly detailed.

Regulatory forces present both a hurdle and a potential moat. The U.S. Food and Drug Administration (FDA) regulates LAAO devices as Class III (high-risk) medical devices, requiring pre-market approval (PMA) supported by substantial clinical trial data. This pathway is costly and time-intensive, typically requiring a randomized controlled trial against anticoagulation therapy. However, this high barrier to entry also protects the market from rapid commoditization. Macro forces include ongoing pressure on healthcare costs, which incentivizes payers to adopt technologies that reduce long-term expenditure, even with higher upfront device costs, provided robust cost-effectiveness data is available.

Metric Value
Global LAA Closure Device Market 2023 1.2 $B
Projected CAGR 2024-2030 15 %

The projected market growth underscores a receptive commercial environment, but the cited figure represents the entire existing device category, not Spheric Bio's unproven share. The company's success hinges on capturing a portion of this growth by demonstrating superior clinical outcomes, not merely riding the market tailwind.

Data Accuracy: YELLOW, Market sizing is drawn from an analogous third-party analyst report for the broader device category. Clinical demand drivers are well-established in public health data and cardiology literature, but specific linkage to Spheric Bio's commercial potential is not yet corroborated by independent commercial analysis.

Competitive Landscape

MIXED Spheric Bio is entering a medical device segment defined by established, multi-billion dollar incumbents, where its primary claim to a foothold is a novel, personalized approach to a standard procedure.

Company Positioning Stage / Funding Notable Differentiator Source
Spheric Bio Personalized LAAO implants grown in vivo from biomaterials. Preclinical; undisclosed funding. [PUBLIC] Implant conforms and self-heals to patient anatomy post-deployment; aims to reduce complications. [MIT IMES, Mar 2025]
Boston Scientific Market leader with WATCHMAN FLX device, a nitinol mesh plug. Public company; mature commercial stage. Extensive clinical data, global sales infrastructure, and established physician training protocols. Company website
Abbott Major incumbent with AMPLATZER Amulet device, a dual-seal nitinol plug. Public company; mature commercial stage. Dual-seal design for occlusion; long-standing brand recognition in structural heart. Company website
Conformal Medical Challenger with the CLAAS device, a foam-based implant conforming to anatomy. Clinical-stage; raised $85M Series C in 2023. [PUBLIC] Conformable foam technology designed to fit a wider range of anatomies than rigid plugs. Crunchbase

The competitive map in left atrial appendage occlusion is bifurcated. On one side are the entrenched incumbents, Boston Scientific and Abbott, which dominate through scale, clinical heritage, and deep integration into hospital catheterization labs. Their devices are the procedural standard, and their primary competition is with each other for market share. On the other side are a handful of clinical-stage challengers, like Conformal Medical, seeking to displace the leaders with next-generation designs that promise better fit and fewer complications. Spheric Bio sits in this latter challenger cohort but proposes a more radical technological departure, moving from pre-formed metal or foam devices to a liquid or gel biomaterial that solidifies in situ.

Spheric Bio's current, and likely most durable, edge is its academic and technical foundation. The co-founding team's affiliation with MIT and Harvard provides access to specialized biomaterials research and early validation through institutional prizes. The core differentiator, the ability to create a patient-specific implant after catheter delivery, is a material science innovation rather than an incremental design tweak. This edge is perishable, however. It depends entirely on translating preclinical promise into clinical safety and efficacy data, a process that requires significant capital and time. Competitors with commercial devices are already generating real-world evidence and refining their sales tactics, while Spheric Bio's technology remains in the lab.

The company's most significant exposure is to the commercial and regulatory execution of its nearer-term challenger peers. Conformal Medical, for instance, is already in clinical trials with a substantial war chest. If Conformal's foam-based device demonstrates superior clinical outcomes and gains FDA approval, it could establish a new standard for "conformability" that would be difficult for a later, more complex biomaterial approach to dislodge. Furthermore, Spheric Bio does not own any clinical or commercial channel. Its initial plan to work with academic medical centers is a common starting point, but it lacks the dedicated field clinical specialists and reimbursement expertise that the incumbents deploy as a formidable barrier to entry.

The most plausible 18-month scenario sees the LAAO market continuing to be dominated by the incumbents, with share shifts between them based on new data releases. Among challengers, the winner will be the one that first crosses the regulatory finish line with compelling data. If Conformal Medical publishes positive pivotal trial results and secures FDA approval, it will capture the mindshare of interventional cardiologists looking for a modern alternative, potentially boxing out earlier-stage concepts. Spheric Bio would be a loser in a scenario where grant funding stalls or preclinical translation hits unexpected biological hurdles, delaying its entry into clinical studies and ceding the innovation narrative to better-capitalized rivals.

Data Accuracy: YELLOW -- Competitor profiles for Boston Scientific and Abbott are well-established; Conformal Medical funding and stage are confirmed via Crunchbase. Spheric Bio's differentiation claims are from a single institutional source.

Opportunity

PUBLIC

If Spheric Bio can successfully translate its academic platform into a commercial product, the prize is a dominant position in a high-value segment of the structural heart device market, where personalization could command a premium and reduce costly complications.

The headline opportunity is to become the category-defining standard for left atrial appendage occlusion (LAAO), displacing current one-size-fits-all devices with a personalized, biomaterial-based implant. This outcome is reachable because the core technical premise,using a catheter-delivered material that expands and self-heals to custom-fit a patient's anatomy,has been validated in early animal testing [MIT IMES, Mar 2025]. CEO Connor Verheyen has framed the clinical advantage in specific terms, claiming the approach allows for "complete closure of the appendage for every patient, every time" and reduces device-related complications [MIT IMES, Mar 2025]. In a procedure where incomplete closure is a known failure mode for existing devices, a technology that reliably achieves a perfect seal could shift clinical practice and payer reimbursement, creating a durable first-mover advantage.

Multiple paths exist for the company to scale from an academic proof-of-concept to a commercial platform.

Scenario What happens Catalyst Why it's plausible
Academic Beachhead The company initiates its first-in-human studies at a top-tier academic medical center, generating peer-reviewed clinical data. Securing an investigational device exemption (IDE) from the FDA to begin a pilot study. The team's MIT and Harvard affiliations provide direct pathways to clinical collaborators; the company has stated plans to "initiate at academic medical centers" post-spinout [YouTube IdeaStream, 2025].
Platform Expansion The biomaterial delivery platform is validated for a second structural heart application, such as paravalvular leak closure or septal defect repair. Successful LAAO clinical data demonstrates the platform's safety and adaptability. The company describes its work as a "platform to create personalized medical implants" [Deshpande Center, 2024], suggesting the underlying technology is designed for multiple indications beyond the initial cardiac wedge.

Compounding for Spheric Bio would manifest as a clinical data moat. Each successful implant procedure would generate unique anatomical fit data, reinforcing the algorithm that informs the biomaterial's deployment and healing characteristics. This dataset could improve future device iterations and streamline the regulatory pathway for expanded indications. Early signs of this flywheel are not yet present, as the company remains in preclinical testing, but the platform's design inherently creates this feedback loop. The more patients treated, the more refined and predictable the personalized outcome becomes, potentially creating a barrier for followers who lack equivalent procedural experience.

The size of the win can be contextualized by looking at the established market for LAAO devices. Boston Scientific, a direct competitor, reported global sales of its Watchman device of approximately $1.9 billion in 2023 [Boston Scientific Annual Report, 2024]. If Spheric Bio's personalized approach were to capture a meaningful portion of this existing market,or expand the total addressable population by improving safety and efficacy,the company could represent a multi-billion dollar asset. A credible comparable is the 2013 acquisition of Atritech by Boston Scientific for up to $375 million to acquire the Watchman technology, which at the time was still investigational [MedCity News, 2013]. A successful platform with clinical validation could command a significant premium in a strategic acquisition or, in a bullish scenario, support an independent public valuation in the low billions (scenario, not a forecast).

Data Accuracy: YELLOW -- Opportunity framing relies on cited product claims and market context; specific commercial outcomes and comparables are extrapolated from public data on adjacent companies.

Sources

PUBLIC

  1. [Deshpande Center, 2024] Spheric Bio | https://deshpande.mit.edu/spinouts/spheric-bio/

  2. [MIT News, Mar 2025] A personalized heart implant wins MIT Sloan health care prize | https://news.mit.edu/2025/personalized-heart-implant-wins-mit-sloan-health-care-prize-0303

  3. [MIT IMES, Mar 2025] A personalized heart implant wins MIT Sloan health care prize | https://imes.mit.edu/news-events/personalized-heart-implant-wins-mit-sloan-health-care-prize

  4. [YouTube IdeaStream, 2025] Spheric Bio - 3D Heart Implant to Help Prevent Strokes | https://www.youtube.com/watch?v=vk7sRmLyLKc

  5. [WB Journal] Cambridge startup wins UMass Chan, UMass Lowell seed funding contest | https://wbjournal.com/article/cambridge-startup-wins-umass-chan-umass-lowell-seed-funding-contest/

  6. [MIT PKG Center, 2025] Nutur and Dheera Ananthakrishnan ’90, MBA ’23 Awarded MIT Sloan Healthcare Innovation Prizes! - PKG | https://pkgcenter.mit.edu/nutur-and-dheera-ananthakrishnan-90-mba-23-featured-in-mit-news/

  7. [CDC] Atrial Fibrillation | https://www.cdc.gov/heartdisease/atrial_fibrillation.htm

  8. [Grand View Research, 2024] Left Atrial Appendage Closure Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/left-atrial-appendage-closure-devices-market

  9. [American College of Cardiology] Left Atrial Appendage Occlusion | https://www.acc.org/tools-and-practice-support/clinical-toolkits/structural-heart-disease-left-atrial-appendage-occlusion

  10. [Boston Scientific Annual Report, 2024] Boston Scientific 2023 Annual Report | https://investors.bostonscientific.com/financial-information/annual-reports

  11. [MedCity News, 2013] Boston Scientific Buys Atritech for $375M to Get Watchman LAA Closure Device | https://medcitynews.com/2013/01/boston-scientific-buys-atritech-for-375m-to-get-watchman-laa-closure-device/

Articles about Spheric Bio

View on Startuply.vc